Emergent BioSolutions secures $52.7M contract modification from ASPR for ACAM2000 supply

Emergent BioSolutions Inc.

$52.7M modification exercises Option Year 7 under existing 10-year ASPR contract.
Deliveries of ACAM2000 vaccine, ancillaries, and diluent begin June 2026; diluent balance by December 2026.
Contract supports U.S. government smallpox and mpox preparedness and response needs.
Modification follows recent ACAM2000 approvals for mpox in Saudi Arabia and Singapore.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.